Get started
Author

Shyeilla V. Dhuria

Intranasal delivery to the central nervous system: Mechanisms and experimental considerations
2009 · Shyeilla V. Dhuria, Leah R. Hanson, et al. · Journal of Pharmaceutical Sciences · 1,262
Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors
2014 · Jeffrey R. Infante, E. Claire Dees, et al. · Journal of Clinical Oncology · 210
PDF
Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system
2008 · Shyeilla V. Dhuria, Leah R. Hanson, et al. · Journal of Pharmaceutical Sciences · 135
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study
2016 · G. Curigliano, P. Gómez Pardo, et al. · The Breast · 134
PDF
Novel Vasoconstrictor Formulation to Enhance Intranasal Targeting of Neuropeptide Therapeutics to the Central Nervous System
2008 · Shyeilla V. Dhuria, Leah R. Hanson, et al. · Journal of Pharmacology and Experimental Therapeutics · 104
Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations
2017 · Tanay S. Samant, Shyeilla Dhuria, et al. · Clinical Pharmacology & Therapeutics · 82
PDF
Ribociclib Drug‐Drug Interactions: Clinical Evaluations and Physiologically‐Based Pharmacokinetic Modeling to Guide Drug Labeling
2020 · Tanay S. Samant, Felix Huth, et al. · Clinical Pharmacology & Therapeutics · 53
Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2–) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis.
2016 · Dejan Juric, Pamela N. Munster, et al. · Journal of Clinical Oncology · 33
A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma
2019 · Andrew Spencer, Aaron Seth Rosenberg, et al. · Clinical Lymphoma Myeloma & Leukemia · 30
Abstract 2775: A phase I study of LCL161, an oral IAP inhibitor, in patients with advanced cancer
2010 · Jeffrey R. Infante, E. Claire Dees, et al. · Cancer Research · 24
Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trial
2025 · Brittany N. Flores, Seungyoon B. Yu, et al. · Nature Communications · 23
PDF
Food consumption and activity levels increase in rats following intranasal Hypocretin-1
2016 · Shyeilla V. Dhuria, Jared M. Fine, et al. · Neuroscience Letters · 23
Time‐Dependent Inhibition and Induction of Human Cytochrome P4503A4/5 by an Oral IAP Antagonist, LCL161, In Vitro and In Vivo in Healthy Subjects
2013 · Shyeilla Dhuria, Heidi Einolf, et al. · The Journal of Clinical Pharmacology · 23
Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3.
2016 · Peter A. Fasching, Guy Heinrich Maria Jerusalem, et al. · Journal of Clinical Oncology · 14
Abstract P6-11-06: A phase Ib study of LCL161, an oral inhibitor of apoptosis (IAP) antagonist, in combination with weekly paclitaxel in patients with advanced solid tumors
2012 · R Dienstmann, L Vidal, et al. · Cancer Research · 13
The Integrated Stress Response Is Modulated by eIF2B Agonist DNL343: Results From Phase 1 Healthy Subject and Phase 1b ALS Patient Studies. (P8-8.010)
2023 · Linus Sun, Richard Tsai, et al. · Neurology · 9
LBA1 First-line ribociclib + letrozole in postmenopausal Asian women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2
2016 · Y.S. Yap, L-M. Tseng, et al. · Annals of Oncology · 9
Phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) in combination with either tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with HR+, HER2- advanced breast cancer (aBC): MONALEESA-7.
2015 · Debu Tripathy, Aditya Bardia, et al. · Journal of Clinical Oncology · 8
No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects
2019 · Taylor Choi, Allison S. Komirenko, et al. · Clinical Pharmacology in Drug Development · 7
1400. Mass Balance, Metabolism, and Excretion of [14C]-Plazomicin in Healthy Human Subjects
2018 · Taylor Choi, Julie D Seroogy, et al. · Open Forum Infectious Diseases · 6
Ribociclib + letrozole for first-line treatment of HR+, HER2− ABC: efficacy, safety, and pharmacokinetics
2016 · F. André, S.M. Stemmer, et al. · European Journal of Cancer · 4
A phase I food-effect study of the ribociclib (LEE011) drug-in-capsule (DiC) formulation in healthy subjects.
2015 · Shyeilla V. Dhuria, Ravi Siddani, et al. · Journal of Clinical Oncology · 4
DNL310 normalizes primary storage substrates and biomarkers of lysosomal dysfunction in neuronopathic MPS II: 2-year interim analysis of a phase 1/2 study
2023 · Akhil Bhalla, Khishig Tsogtbaatar, et al. · Molecular Genetics and Metabolism · 2
Use of a secure mobile application to inform clinicians on adverse event management and drug-drug interactions for ribociclib: Experiences with CT scholar in ribociclib clinical trials.
2017 · Tania Small, Najla Bugazia, et al. · Journal of Clinical Oncology · 1
Abstract PD5-7: Phase Ib study of LCL161, an oral antagonist of inhibitor of apoptosis proteins, in combination with weekly paclitaxel in patients with advanced solid tumors: Safety and efficacy results, including breast cancer cohort
2013 · R Dienstmann, B Adamo, et al. · Cancer Research · 1
Works count: 31
Citation count: 2,214
H-index: 14
I10-index: 15
Year
Topic
Type